An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects

Novo Nordisk A/S3,024 enrolled

Overview

This study is conducted in Asia. The aim of this observational study is to evaluate the side effects profile and benefits of using intravenous insulin aspart infusion in hospitalised subjects under normal clinical practice conditions in India.

Study Type

OBSERVATIONAL

Enrollment

3,024

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions

insulin aspartDRUG

Intravenous NovoRapid dose \& frequency as decided by treating physician

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Any hospitalized subject with hyperglycaemia requiring intravenous insulin therapy is eligible for the study based on the discretion of the physician. Exclusion Criteria: * Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude; * Subjects with a hypersensitivity to NovoRapid or to any of the excipients. * Subjects with conditions considered as contraindications.

Locations (1)

Novo Nordisk Investigational Site

Bangalore, India

Outcomes

Primary Outcomes

Incidence of AEs (adverse event)

Time frame: After 6 months

Incidence of SAEs (serious adverse event)

Time frame: After 6 months

Secondary Outcomes

Other safety & efficacy measures

Time frame: After 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.